Adoptive Transfer of Autologous T Cells Targeted to Prostate-Specific Membrane Antigen for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Protocol
09-036
Full Title
Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)
Phase
I
Purpose

This phase I study will evaluate the safety and effectiveness of different doses of a patient’s own immune cells (T cells) which have been changed to help recognize and destroy his prostate cancer cells by targeting a protein called prostate-specific membrane antigen. The T cells are removed from the patient’s blood, modified with a gene in the laboratory so they are better able to recognize and kill prostate cancer cells, and then returned to the patient’s body. This gene is inserted into the T cells using a weakened virus. /

It is hoped that this approach will help each patient’s own T cells recognize his prostate cancer cells and possibly kill them.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have metastatic prostate cancer that has not yet been treated with chemotherapy. Patients may have had hormonal therapy.
  • Patients must have rising PSA levels and a serum testosterone level under 50 ng/mL.
  • Patients must be age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. Susan F. Slovin at 646-422-4470 or Dr. Howard Scher at 646-422-4330.

Disease(s)
Prostate Cancer
Prostate Cancer: Metastatic Disease after Hormone-Reducing Therapy
Locations
Related Diseases

Cancer Clinical Trials: Personalizing for Each Patient

Join our experts for a discussion of clinical trials on November 18. Clinical trials can give patients access to new drugs and other treatments before they are widely available, but how do you know if a trial is right for you?

Learn more »